Opendata, web and dolomites

TruVue

A novel and easy to interpret patient safety monitor, for the diagnosis and management of cardiac function, fluid delivery and drug administration during surgery and intensive care.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TruVue project word cloud

Explore the words cloud of the TruVue project. It provides you a very rough idea of what is the project "TruVue" about.

truvue    outcomes    meet    trial    simply    blood    unplanned    stroke    flow    complications    loops    hemodynamic    failing    return    monitoring    mortality    situation    paris    revenues    infarctions    deltex    plan    visual    multinational    sooner    annually    day    monitors    contribution    interface    discharge    business    gui    truly    seed    lariboisiere    provides    envisages    inadequate    errors    thousands    patients    2020    12    sales    graphical    globally    financial    input    interaction    readmissions    publications    opportunity    velocity    234    days    die    shorter    serious    ce    worldwide    reduce    unacceptable    population    full    lives    42    care    costed    uses    presented    save    marked    events    clinical    haemodynamic    multicentre    admissions    safety    enter    injury    pressure    simultaneous    intensive    instability    investment    51    obtain    stay    generate    ages    hospital    adverse    patient    lifespan    frequent    aortic    protecting    million    surgery    fold    undergo    display    faces    myocardial    healthcare    13    kidney    diagnostic    centres    longer   

Project "TruVue" data sheet

The following table provides information about the project.

Coordinator
DELTEX MEDICAL LIMITED 

Organization address
address: TERMINUS ROAD
city: CHICHESTER
postcode: PO19 8TX
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.deltexmedical.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2017-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DELTEX MEDICAL LIMITED UK (CHICHESTER) coordinator 50˙000.00

Map

 Project objective

Worldwide 234 million patients undergo major surgery annually. One million will die within 30 days. A further 42 million simply die up to 13 years sooner due to complications and 12 million will enter intensive care in the EU and US. This unacceptable situation has the potential to increase Deltex’s revenues 5 fold by 2020 through the development of TruVue. Of the adverse events 51% are directly due to inadequate haemodynamic management. Hemodynamic instability and low blood pressure are frequent, with consequences such as myocardial infarctions, stroke and kidney injury. Complications have serious clinical and financial consequences; unplanned intensive care admissions; longer stay; increased readmissions; increased 30 day mortality; and shorter patient lifespan after discharge. Healthcare faces increasingly complex cases as the population ages and uses ever more complex equipment. Protecting patients from haemodynamic errors through improved monitoring should save thousands of lives, improve outcomes and reduce costs. Diagnostic haemodynamic equipment needs to display the interaction of flow and pressure if it is to be truly effective. Current monitors are failing to meet this need. Deltex and Lariboisiere Hospital Paris have developed the novel TruVue Velocity Pressure Loops system. TruVue provides simultaneous visual display of the patient’s aortic blood flow velocity and aortic blood pressure; and will be a significant contribution to patient safety. TruVue has been CE-marked and is in use at Lariboisiere Hospital. This phase 1 project has two aims: to obtain user input to enhance the Graphical User Interface (GUI); and to cost a multinational multicentre clinical trial for phase 2 application. Deltex envisages that the clinical trial will generate publications, ‘seed’ leading centres and promote the TruVue within the EU and globally. A full assessment of the sales opportunity and return on investment will be presented as part of a fully-costed business plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRUVUE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRUVUE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

Assist (2015)

Telocate ASSIST – Development and marketing of an acoustic solution for localization and navigation of people in buildings using the smartphone

Read More  

Digital Iris (2018)

Bringing the human being into the digital loop

Read More  

BioAhead (2017)

BioAhead – an innovative optimization algorithm for amino acid chain analytics

Read More